Comprehensive Review of Cannabinoid Pharmacology, Receptor Systems, and Therapeutic Applications
This broad review covers 15 years of cannabinoid receptor research, cataloging therapeutic properties including pain relief, muscle relaxation, anti-inflammation, appetite stimulation, and neuroprotection, while noting emerging research into CB receptor antagonists for obesity and addiction.
Quick Facts
What This Study Found
This comprehensive review covered 15 years of research since the discovery of the endocannabinoid system. It detailed two G-protein coupled cannabinoid receptors (CB1 and CB2), endocannabinoids produced "on demand" from membrane lipids, and the distribution of cannabinoid receptors across the central nervous system and peripheral tissues including immune, reproductive, gastrointestinal, cardiovascular, and endocrine systems.
Therapeutic properties of CB receptor agonists identified include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, mood improvement, appetite stimulation, antiemesis, lowered intraocular pressure, bronchodilation, neuroprotection, and antineoplastic effects.
Clinical research at the time focused on chronic pain and neurological disorders. CB receptor antagonists were under investigation for obesity and nicotine addiction, with additional potential proposed for alcohol and heroin dependency, schizophrenia, Parkinson's disease, and Alzheimer's disease.
Key Numbers
Two receptor subtypes: CB1 and CB2. Main endocannabinoids: anandamide and 2-AG. Receptors found in: CNS, immune system, reproductive tract, GI tract, sympathetic ganglia, endocrine glands, arteries, lung, heart. Therapeutic properties cataloged: 12+ distinct actions.
How They Did This
Comprehensive narrative review covering 15 years of research on the endocannabinoid system, cannabinoid receptors, endogenous ligands, synthetic modulators, and therapeutic applications. Covered pharmacology, receptor distribution, and both agonist and antagonist therapeutic potential.
Why This Research Matters
This review provides one of the most complete snapshots of cannabinoid pharmacology as of 2005, documenting the remarkable breadth of biological processes influenced by the endocannabinoid system. The fact that both agonists and antagonists show therapeutic potential highlights the complexity of this signaling system.
The Bigger Picture
The breadth of cannabinoid receptor distribution across the body explains why cannabis affects so many different systems. This review captures a pivotal moment when research was expanding from understanding basic pharmacology toward developing targeted therapeutics for specific conditions.
What This Study Doesn't Tell Us
As a narrative review, it does not systematically evaluate the quality of evidence for each therapeutic application. Many therapeutic claims were based on preclinical data. The rapid pace of research means some conclusions were quickly superseded.
Questions This Raises
- ?Which of the many identified therapeutic properties will prove clinically useful in humans?
- ?Can CB receptor antagonists succeed as treatments for obesity and addiction?
Trust & Context
- Key Stat:
- Cannabinoid receptors distributed across CNS, immune, reproductive, GI, cardiovascular, and endocrine systems
- Evidence Grade:
- Comprehensive narrative review from a leading cannabinoid researcher. Provides an authoritative overview but includes preclinical and clinical evidence without systematic quality assessment.
- Study Age:
- Published in 2005 by Franjo Grotenhermen, a prominent cannabinoid researcher. Many therapeutic applications discussed have since been tested in clinical trials.
- Original Title:
- Cannabinoids.
- Published In:
- Current drug targets. CNS and neurological disorders, 4(5), 507-30 (2005)
- Authors:
- Grotenhermen, Franjo(4)
- Database ID:
- RTHC-00190
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does cannabis affect so many different body systems?
Cannabinoid receptors are distributed throughout the body, not just in the brain. They are found in the immune system, digestive tract, heart, lungs, reproductive system, and endocrine glands, which is why cannabis use can affect such a wide range of body functions.
Can cannabinoid receptor blockers treat obesity?
As of this 2005 review, CB receptor antagonists were under investigation for obesity treatment. The concept was that blocking cannabinoid receptors involved in appetite stimulation could reduce food intake. Rimonabant was later approved but withdrawn due to psychiatric side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-your-body-what-research-shows
- why-does-weed-make-you-hungry-munchies
- why-does-weed-make-food-taste-better
- cannabis-and-arthritis-research
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00190APA
Grotenhermen, Franjo. (2005). Cannabinoids.. Current drug targets. CNS and neurological disorders, 4(5), 507-30.
MLA
Grotenhermen, Franjo. "Cannabinoids.." Current drug targets. CNS and neurological disorders, 2005.
RethinkTHC
RethinkTHC Research Database. "Cannabinoids." RTHC-00190. Retrieved from https://rethinkthc.com/research/grotenhermen-2005-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.